WEE1 and glioblastoma: Interestingly, Debio-0123 is in clinical trials in combination with standard treatment regimens, including radiotherapy for glioblastoma (GBM) patients (NCT05765812), as preclinical evidence has demonstrated its enhanced ability to cross the blood–brain barrier compared to previous Wee1 inhibitors [93].